Annovis is also seeking fresh capital while working to advance trials for both Alzheimer's and Parkinson's disease drugs.

The FDA has set a Prescription Drug User Fee Act action date for 24 May 2026.

From Science.org. "T3D Therapeutics alleges that contract researchers delivered “medically impossible” results on its candidate drug. In 2023, the drug ...

In 2021, the fda approved a treatment that claims to stop Alzheimer's at the source, removing the plaques in the brain long ...

Alzheimer’s may be driven far more by genetics than previously thought, with one gene playing an outsized role. Researchers ...

Memantine, a long-approved and cost-effective drug used to treat Alzheimer's disease, could also benefit patients with sickle ...

America has an Alzheimer’s problem, devastating families and driving soaring healthcare costs. More than 7 million people over 65 years old live with Alzheimer’s dementia today, a number predicted to ...

Following the hard-won success of early anti-amyloid drugs, a new generation of Alzheimer’s modalities—from tau-targeting ...

Actinogen Medical soon should find out whether its pivotal Xanamia Alzheimer's trial is futile, or hitting the right notes. .

Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its ...

Researchers have created a targeted compound that blocks an enzyme linked to inflammation in individuals with a genetic predisposition to Alzheimer’s disease, while still maintaining normal brain ...

Early in Alzheimer’s disease, your brain can begin to change long before anyone notices a lost name or missed appointment.